The Sequencing Kits Market is projected to reach $21.9 billion by 2030, at a CAGR of 15.3% from 2023 to 2030. The increasing number of sequencing projects, the rise in cancer cases, and the increasing R&D activities by pharmaceutical & biotechnology companies have increased the demand for NGS sequencing kits & reagents in current use. The emergence of advanced sequencing technologies that enable the sequencing of DNA or RNA more quickly and at a lower cost has gained traction due to its increasing applications in the areas of genomics research, oncology, and reproductive health.
Furthermore, whole genome sequencing is frequently conducted in clinical settings, particularly for genetic and chronic diseases. In the case of rare genetic diseases where no specific mutations have been observed using other molecular tests, advanced sequencing technologies are used for whole genome sequencing. According to a review published in the Genome Medicine journal, 300–400 million people worldwide are affected by rare diseases. Also, about 80% of these diseases have genetic causes. According to the United Nations (UN), the global incidence of Down syndrome ranges from 1 in 1,000 to 1 in 1,100 live births. About 3,000 to 5,000 children are born with this chromosome disorder every year. Thus, the demand for NGS kits & reagents for cancer research and diagnosis is expected to grow significantly in the coming years.
The growth of the sequencing kits market is driven by the increasing prevalence of cancer and genetic disorders, rising healthcare expenditures, increasing funding for research activities, the surge in genome mapping programs, the decreasing costs of sequencing procedures, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, the improving regulatory and reimbursement scenarios for NGS-based diagnostic tests, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of NGS kits & reagents and the ethical & legal issues related to DNA sequencing-based diagnosis are factors restraining the growth of this market.
Moreover, government support for large-scale genomic sequencing projects, the increasing applications of genome sequencing in disease diagnostics and precision medicine, and advancements in genomics & proteomics are expected to generate growth opportunities for market stakeholders. However, the evolving regulatory landscape, the low chances of positive, actionable mutations, and the lack of sequencing professionals in developing countries are major challenges for market growth.
Developing portable sequencing technologies and increasing partnerships & collaborations among NGS product manufacturers to expand and improve product offerings are prominent trends in the sequencing kits market.
Advanced sequencing technologies have accelerated biological & medical research and discovery, allowing biologists and medical scientists to collect massive amounts of DNA sequence data rapidly and cost-effectively. In 2003, the human genome was sequenced for the first time, costing USD 2.7 billion. However, by 2013, the price of sequencing an average human genome had reduced to just a few thousand dollars. As of 2021, genome sequencing costs had declined to around USD 450–850. With the rising demand for sequencing, providers are expected to further lower prices in the coming years as their sequencing costs per sample are likely to reduce. Market players are focused on launching advanced sequencing instruments that reduce sequencing costs.
Increasing Applications of Genome Sequencing in Disease Diagnostics and Precision Medicine is Creating Market Growth Opportunities
Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. The synthesis of genes can rapidly sequence large sections of a person’s genome and aid in the formulation of precision medicine, generating cost-effective alternatives for existing therapies and allowing for novel treatments in multiple areas, including infectious diseases, drug discovery, and reproductive health, among others. Personalized medicine analyzes molecules, individual genes, and networks and translates them into an overall output for the systems of the human body.
Furthermore, with the utilization of sequencing technologies in precision medicine, cancer treatment and diagnosis are also advancing significantly. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology, a rapidly developing field that has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with sequencing. Thus, the increasing inclination toward personalized medicine-based diagnosis and treatment is expected to create opportunities for market growth.
The Increasing Prevalence of Cancer & Genetic Disorders is Driving the Growth of the Sequencing Kits Market
The burden of cancer is growing globally. According to GLOBOCAN 2020, cancer incidence is expected to increase from 19.3 million in 2020 to 30.2 million in 2040. Moreover, mortalities due to cancer are estimated to increase from 9.9 million in 2020 to 16.3 million in 2040. Nearly 70% of the total deaths due to cancer occur in low and middle-income countries. Early detection is extremely important in reducing mortality, improving patients’ chances of survival, and saving on treatment costs. Various sequencing technologies are used for whole-genome sequencing, tumor-normal comparisons, and targeted gene profiling to deliver treatments based on insights gained from sequencing.
Advanced sequencing technologies, such as nanopore sequencing and single-molecule real-time sequencing, are gaining popularity in cancer research due to their rapid speed, high accuracy, and low costs. This strategy customizes treatments based on the specific molecular changes causing a disease. In oncology, sequencing technologies are essential for analyzing patient biopsy samples, helping oncologists identify appropriate treatments that target the genetic abnormalities responsible for tumor growth. Thus, the growing applications of genome sequencing in cancer therapy and genetic disorders are expected to drive the growth of the sequencing kits market.
Click here to: Get Free Sample Pages of this Report
The number of sequencing projects drives the demand for Sequencing Reagents
Advanced sequencing technologies have accelerated biological & medical research and discovery. Owing to this, many countries have undertaken sequencing projects for various clinical and research purposes. Some of the major global genome sequencing projects are as follows:
Based on Type, the Nucleic Acid Extraction & Amplification Kits Segment is Expected to Account for 33% of the Market in 2023
The large market share of this segment is attributed to the high adoption of sequencing-based research and development by various end users, such as pharmaceutical & biopharmaceutical companies and academic & research institutes. Also, the increasing applications of sequencing in reproductive health, oncology, agriculture, and animal research have triggered the demand for nucleic acid extraction & amplification kits & reagents.
Based on Technology, the Next-generation Sequencing (NGS) Segment is Expected to Account for the Largest Share of the Market in 2023
The large market share of this segment is attributed to the benefits offered by NGS, such as high-throughput production, efficient instrument runs, and cost-effectiveness compared to traditional first-generation sequencing methods. Additionally, NGS is highly preferred for large-scale genomic profiling and transcriptomic sequencing.
Based on Application, the Research Applications Segment is Expected to Account for the Largest Share of 64% of the Market in 2023
The large market share of this segment is attributed to the decreasing cost of sequencing procedures, the rising research and development efforts by pharmaceutical and biopharmaceutical companies in drug and biomarker discovery, the high sensitivity and throughput offered by advanced sequencing technologies, and the expanding applications of sequencing in various clinical and research areas.
Based on End User, the Pharmaceutical & Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market in 2023
The large market share of this segment is attributed to the declining costs of sequencing, the increase in research and development activities by pharmaceutical and biotechnology companies, and the extensive utilization of advanced sequencing products for cancer studies.
Asia-Pacific: Fastest-growing Regional Market
The growth of this regional market is attributed to the accelerated economic growth in many countries across the region, which has increased the focus of governments in these countries on improving the healthcare sector. These government initiatives have led to increased investment to enhance the accessibility of healthcare services, healthcare infrastructure improvements, and biomarker discovery programs. The other key factors supporting the market's growth across this region include the rising prevalence of cancer, the growing adoption of advanced diagnostic and therapeutic technologies, and government initiatives to support genome sequencing programs.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players between 2020 and 2023. The key players profiled in the sequencing kits market report are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).
The major companies in the sequencing kits market have implemented various strategies over the years to expand their product offerings and global footprint and augment their market share. The key strategies by most companies in the sequencing kits market were product launches, product approval & enhancement, agreements, partnerships, collaborations, acquisitions, mergers, and expansion. Partnerships, agreements, and collaborations were key players' most preferred growth strategy, accounting for a 48%-50% share of the total strategic developments from 2020 to 2023, enabling them to increase their product offerings in collaboration with other key players, thereby strategically increasing the revenue. The leading players actively focused on this strategy include Illumina, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), and Qiagen N.V. (Netherlands).
Scope of the Report:
Sequencing Kits Market Assessment, by Type
Sequencing Kits Market Assessment, by Technology
Sequencing Kits Market Assessment, by Application
Sequencing Kits Market Assessment, by End User
Sequencing Kits Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the cancer/tumor profiling market based on type, technology, application, and end user. This report also involves value analysis of various segments and subsegments of the sequencing kits market at the regional and country levels.
The sequencing kits market is projected to reach $21.9 billion by 2030, at a CAGR of 15.3% during the forecast period.
The nucleic acid extraction & amplification kits & reagents segment is expected to account for the largest share of the market in 2023.
The next-generation sequencing (NGS) segment is expected to account for the largest share of the market in 2023. The large market share of this segment is attributed to the higher sensitivity of this technique to call variants, low sequencing costs compared to other sequencing technologies, and the availability of low-cost sequencers.
The research applications segment is expected to hold the largest share of the market in 2023. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced sequencing technologies like NGS and SMRT within research protocols.
The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the market in 2023. The large market share of this segment is attributed to rising research efforts in drug discovery, the growing demand for precision medicine, and the increasing number of cancer studies aimed at advancing cancer treatment.
The growth of the sequencing kits market is driven by the increasing prevalence of cancer & genetic disorders, rising healthcare expenditures, increasing funding for research activities, the surge in genome mapping programs, the decreasing costs of sequencing procedures, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, the improving regulatory and reimbursement scenarios for NGS-based diagnostic tests, and government initiatives promoting the use of sequencing in clinical & research applications.
The key players profiled in the sequencing kits market study are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).
Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising investments in the healthcare sector and increasing genomic projects in these countries. China has the largest burden of rare genetic diseases globally. Currently, 10 million individuals in China have some chromosomal defect, and over 1 million have monogenic diseases. Down Syndrome (DS) is the most prevalent, with 1 in 700 births. Despite being increasingly recognized as a major health issue, managing rare genetic diseases in China still needs significant improvement. In recent years, government-sponsored programs for public awareness and screening of rare genetic diseases have played an important role in disease prevention. Such programs are expected to increase the utilization of various sequencing technologies, including sequencing kits & reagents.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Pricing Analysis
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Europe
4.4.3. Asia-Pacific
4.4.3.1. China
4.4.3.2. Japan
4.4.3.3. India
4.4.4. Latin America
4.4.5. Middle East
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
5. Sequencing Kits & Reagents Market Assessment—by Type
5.1. Overview
5.2. Nucleic Acid Extraction & Amplification Kits & Reagents
5.3. Sequencing Kits & Reagents
5.4. Library Preparation Kits & Reagents
5.5. Control Kits & Reagents
5.6. Other Kits & Reagents
6. Sequencing Kits & Reagents Market Assessment—by Technology
6.1. Overview
6.2. Next-generation Sequencing
6.3. Sanger Sequencing
6.4. Third & Fourth-generation Sequencing
6.5. Other Sequencing Technologies
7. Sequencing Reagents & Kits Market Assessment—by Application
7.1. Overview
7.2. Research Applications
7.2.1. Drug Discovery
7.2.2. Agricultural & Animal Research
7.2.3. Other Research Applications
7.3. Clinical Applications
7.3.1. Oncology
7.3.2. Reproductive Health
7.3.3. Infectious Diseases
7.3.4. Other Clinical Applications
8. Sequencing Reagents & Kits Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Hospitals & Diagnostic Laboratories
8.4. Academic & Research Institutes
8.5. Other End Users
9. Sequencing Kits & Reagents Market Assessment— by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis (2022)
10.5.1. Illumina, Inc. (U.S.)
10.5.2. Thermo Fisher Scientific Inc. (U.S.)
10.5.3. Beijing Genomics Institute (BGI) (China)
10.5.4. QIAGEN N.V. (Netherlands)
10.5.5. Agilent Technologies, Inc. (U.S.)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Illumina, Inc.
11.2. Thermo Fisher Scientific Inc.
11.3. Beijing Genomics Institute (BGI)
11.4. QIAGEN N.V.
11.5. Agilent Technologies, Inc.
11.6. F. Hoffmann-La Roche Ltd
11.7. PerkinElmer, Inc. (Renamed as Revvity)
11.8. Pacific Biosciences of California, Inc.
11.9. Danaher Corporation
11.10. Bio-Rad Laboratories, Inc.
11.11. Oxford Nanopore Technologies Plc.
11.12. 10X Genomics, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Number of New Cancer Cases, by Type, 2020 VS. 2030
Table 2 Common Genetic Disorders: Rates of Occurrence
Table 3 Major Global Sequencing Projects
Table 4 Health Expenditure, by Country
Table 5 Sequencing Kits & Reagents Price List
Table 6 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
Table 7 Global Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 8 Global Nucleic Acid Extraction & Amplification Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 9 Global Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 10 Global Library Preparation Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Control Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Other Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 13 Global Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 14 Global NGS Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Sanger Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 16 Global Third & Fourth-generation Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Sequencing Kits & Reagents Market for Other Sequencing Technologies, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 19 Global Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 20 Global Sequencing Kits & Reagents Market for Research Applications, by Country/Region, 2021–2030 (USD Million)
Table 21 Global Sequencing Kits & Reagents Market for Drug Discovery, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Sequencing Kits & Reagents Market for Agriculture & Animal Research, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Sequencing Kits & Reagents Market for Other Research Applications, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 25 Global Sequencing Kits & Reagents Market for Clinical Applications, by Country/Region, 2021–2030 (USD Million)
Table 26 Global Sequencing Kits & Reagents Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 27 Global Sequencing Kits & Reagents Market for Reproductive Health, by Country/Region, 2021–2030 (USD Million)
Table 28 HIV Prevalence Among Adults, by Region (2020 VS. 2021)
Table 29 Global Sequencing Kits & Reagents Market for Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 30 Global Sequencing Kits & Reagents Market for Other Clinical Applications, by Country/Region, 2021–2030 (USD Million)
Table 31 Global Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 32 Global Sequencing Kits & Reagents Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021–2030 (USD Million)
Table 33 Global Sequencing Kits & Reagents Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 34 Global Sequencing Kits & Reagents Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 35 Global Sequencing Kits & Reagents Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 36 Global Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 37 North America: Sequencing Kits & Reagents Market, by Country, 2021–2030 (USD Million)
Table 38 North America: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 39 North America: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 40 North America: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 41 North America: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 42 North America: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 43 North America: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 44 U.S.: Key Macroindicators & Microindicators
Table 45 U.S.: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 46 U.S.: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 47 U.S.: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 48 U.S.: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 49 U.S.: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 50 U.S.: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 51 Canada: Key Macroindicators & Microindicators
Table 52 Canada: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 53 Canada: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 54 Canada: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 55 Canada: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 56 Canada: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 57 Canada: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 58 Europe: Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 59 Europe: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 60 Europe: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 61 Europe: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 62 Europe: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 63 Europe: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 64 Europe: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 65 Germany: Key Macroindicators & Microindicators
Table 66 Germany: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 67 Germany: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 68 Germany: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 69 Germany: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 70 Germany: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 71 Germany: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 72 France: Key Macroindicators & Microindicators
Table 73 France: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 74 France: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 75 France: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 76 France: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 77 France: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 78 France: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 79 U.K.: Key Macroindicators & Microindicators
Table 80 U.K.: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 81 U.K.: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 82 U.K.: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 83 U.K.: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 84 U.K.: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 85 U.K.: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 86 Italy: Key Macroindicators & Microindicators
Table 87 Italy: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 88 Italy: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 89 Italy: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 90 Italy: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 91 Italy: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 92 Italy: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 93 Spain: Key Macroindicators & Microindicators
Table 94 Spain: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 95 Spain: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 96 Spain: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 97 Spain: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 98 Spain: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 99 Spain: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 100 Estimated Number of New Cancer Cases, by Country, 2020 VS. 2030
Table 101 Rest of Europe: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 102 Rest of Europe: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 103 Rest of Europe: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 104 Rest of Europe: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 105 Rest of Europe: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 106 Rest of Europe: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 107 Asia-Pacific: Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 108 Asia–Pacific: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 109 Asia-Pacific: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 110 Asia-Pacific: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 111 Asia-Pacific: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 112 Asia-Pacific: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 113 Asia-Pacific: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 114 China: Key Macroindicators & Microindicators
Table 115 China: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 116 China: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 117 China: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 118 China: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 119 China: Sequencing Kits & Reagents Market for Clinical Applications, Type, 2021–2030 (USD Million)
Table 120 China: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 121 Japan: Key Macroindicators & Microindicators
Table 122 Japan: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 123 Japan: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 124 Japan: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 125 Japan: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 126 Japan: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 127 Japan: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 128 India: Key Macroindicators & Microindicators
Table 129 India: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 130 India: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 131 India: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 132 India: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 133 India: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 134 India: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 135 Estimated Number of New Cancer Cases, by Country, 2020 VS. 2030
Table 136 Rest of Asia–Pacific: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 137 Rest of Asia–Pacific: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 138 Rest of Asia–Pacific: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 139 Rest of Asia–Pacific: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 140 Rest of Asia–Pacific: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 141 Rest of Asia–Pacific: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 142 Latin America: Sequencing Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 143 Latin America: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 144 Latin America: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 145 Latin America: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 146 Latin America: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 147 Latin America: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 148 Latin America: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 149 Brazil: Key Macroindicators & Microindicators
Table 150 Brazil: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 151 Brazil: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 152 Brazil: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 153 Brazil: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 154 Brazil: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 155 Brazil: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 156 Mexico: Key Macroindicators & Microindicators
Table 157 Mexico: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 158 Mexico: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 159 Mexico: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 160 Mexico: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 161 Mexico: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 162 Mexico: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 163 Rest of Latin America: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 164 Rest of Latin America: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 165 Rest of Latin America: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 166 Rest of Latin America: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 167 Rest of Latin America: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 168 Rest of Latin America: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 169 Middle East & Africa: Sequencing Kits & Reagents Market, by Type, 2021–2030 (USD Million)
Table 170 Middle East & Africa: Sequencing Kits & Reagents Market, by Technology, 2021–2030 (USD Million)
Table 171 Middle East & Africa: Sequencing Kits & Reagents Market, by Application, 2021–2030 (USD Million)
Table 172 Middle East & Africa: Sequencing Kits & Reagents Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 173 Middle East & Africa: Sequencing Kits & Reagents Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 174 Middle East & Africa: Sequencing Kits & Reagents Market, by End User, 2021–2030 (USD Million)
Table 175 Recent Developments, by Company, 2020-2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Sequencing Kits & Reagents Market, by Type, 2023 VS. 2030 (USD Million)
Figure 8 Global Sequencing Kits & Reagents Market, by Technology, 2023 Vs.2030 (USD Million)
Figure 9 Global Sequencing Kits & Reagents Market, by Application, 2023 VS. 2030 (USD Million)
Figure 10 Global Sequencing Kits & Reagents Market, by End User, 2023 VS. 2030 (USD Million)
Figure 11 Global Sequencing Kits & Reagents Market, by Geography, 2023 VS. 2030 (USD Million)
Figure 12 Global Sequencing Kits & Reagents Market: Impact Analysis of Market Drivers, Restraints, Opportunities, And Challenges (2023–2030)
Figure 13 Number of Cancer Cases, by Region, 2020
Figure 14 Genome Sequencing Costs, 2010–2021 (USD/Genome)
Figure 15 Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 VS. 2019 VS. 2020 (USD Million)
Figure 16 Global Pharmaceutical R&D Expenditure, 2014–2028 (USD Billion)
Figure 17 Percentage of Approved Personalized Medicines: Cancer VS. Rare Diseases VS. Other Diseases, 2022
Figure 18 USFDA Regulatory Pathways for IVD Kits
Figure 19 Eu Regulatory Pathway - IVDR 2017/746
Figure 20 China: Medical Device Classification and Premarket Requirements for IVD Products
Figure 21 Porter's Five Forces Analysis
Figure 22 Global Sequencing Kits & Reagents Market, by Type, 2023 Vs 2030 (USD Million)
Figure 23 Global Sequencing Kits & Reagents Market, by Technology, 2023 VS. 2030 (USD Million)
Figure 24 Global Sequencing Kits & Reagents Market, by Application, 2023 VS. 2030 (USD Million)
Figure 25 U.S.: New Molecular Entity (Nme) Approvals
Figure 26 Estimated Number of New Cancer Cases (In Million)
Figure 27 Global Sequencing Kits & Reagents Market, by End User, 2023 VS. 2030 (USD Million)
Figure 28 Global Pharmaceutical R&D Spending, 2014–2026 (USD Billion)
Figure 29 Global Sequencing Kits & Reagents Market, by Geography, 2023 VS. 2030 (USD Million)
Figure 30 North America: Sequencing Kits & Reagents Market Snapshot
Figure 31 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 32 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 33 Europe: Sequencing Kits & Reagents Market Snapshot
Figure 34 Italy: Number of Biotechnology Firms, 2010-2021
Figure 35 Rest of Europe: Pharmaceutical R&D Expenditure, 2020
Figure 36 Asia-Pacific: Sequencing Kits & Reagents Market Snapshot
Figure 37 Latin America: Sequencing Kits & Reagents Market Snapshot
Figure 38 Key Growth Strategies Adopted by Leading Players, 2020– 2023
Figure 39 Sequencing Kits & Reagents Market: Competitive Benchmarking by Technology
Figure 40 Sequencing Kits & Reagents Market: Competitive Benchmarking, by Region
Figure 41 Competitive Dashboard: Sequencing Kits & Reagents Market
Figure 42 Global Sequencing Kits & Reagents Market Share Analysis, by Key Players, 2022 (%)
Figure 43 Illumina, Inc.: Financial Overview (2022)
Figure 44 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 45 Beijing Genomics Institute (BGI): Financial Overview (2022)
Figure 46 Qiagen N.V.: Financial Overview (2022)
Figure 47 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 48 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 49 Perkinelmer, Inc.: Financial Overview (2022)
Figure 50 Pacific Biosciences of California, Inc.: Financial Overview (2022)
Figure 51 Danaher Corporation: Financial Overview (2022)
Figure 52 Bio-Rad Laboratories: Financial Overview (2022)
Figure 53 Oxford Nanopore Technologies Plc.: Financial Overview (2022)
Figure 54 10X Genomics, Inc.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
